Cencora, Inc. has released its earnings for the fiscal quarter and year ending September 30, 2026, demonstrating strong financial performance. The results are significant as they reflect the company's growth trajectory in the competitive wholesale drugs market.

For the fourth quarter, Cencora reported revenues of $88.4 billion, marking a 5.5% increase compared to the previous year. The company achieved a GAAP diluted earnings per share (EPS) of $2.71 and an adjusted diluted EPS of $4.66. For the entire fiscal year, Cencora’s revenue reached $337.4 billion, up 5.0%, with a GAAP diluted EPS of $17.95 and an adjusted diluted EPS of $17.97.

In addition to these results, Cencora has projected that its adjusted diluted EPS for fiscal year 2027 will be in the range of $19.40 to $19.75, reflecting an anticipated growth of 8% to 10%. The company also announced the introduction of new reportable segments along with long-term growth targets for each segment.

The SEC filing, dated November 4, 2026, indicates that the information provided is being furnished and not deemed filed under the Securities Exchange Act of 1934. The company is also conducting a conference call and webcast to discuss these results further, scheduled for 8:30 a.m. Eastern time on the same day.

Cencora operates in the wholesale drugs sector, classified under SIC 5122. This industry is characterized by its role in the distribution of pharmaceuticals and related products, which has seen a surge in demand amid ongoing healthcare challenges. The results from Cencora may set a benchmark for other companies in the industry, including competitors like AmerisourceBergen Corp, which also operates within this space.

The filing does not specify what actions the company will take next following this earnings announcement, but the strong results and future guidance are likely to influence strategic decisions moving forward.